The pharmaceutical giant partners with Insitro to use artificial intelligence and biological data to identify new drug targets for complex diseases
London, 15 October 2026 – AstraZeneca is strengthening its investment in artificial intelligence-driven drug discovery through a partnership with biotechnology company Insitro. The agreement, valued at up to $1.5 billion, aims to identify new treatments for difficult-to-treat liver and heart conditions. The collaboration reflects a growing shift in the pharmaceutical industry, where companies are turning to advanced technology to improve how medicines are discovered and developed.
Under the agreement, AstraZeneca will pay Insitro $40 million upfront. The biotechnology company could receive an additional $1.46 billion through development and commercial milestone payments, depending on the progress and success of the programmes. Insitro may also earn royalties from future medicine sales. AstraZeneca will receive exclusive worldwide rights to advance selected drug programmes developed through the partnership.
The collaboration will focus on two major areas of healthcare. The first is metabolic dysfunction associated steatohepatitis, commonly known as MASH, a serious form of fatty liver disease that can cause inflammation and damage to the liver. The second is cardiomyopathies, a group of conditions that affect the heart muscle and can make it harder for the heart to pump blood effectively. Both areas present significant challenges for researchers seeking more effective treatment options.
Insitro will use its artificial intelligence platform, known as Virtual Human, to study large amounts of human and cellular data. By combining machine learning with biological research, the platform aims to identify the underlying causes of disease and highlight promising targets for new medicines. In simple terms, AI can help researchers recognise patterns in complex scientific information that might otherwise take considerable time to uncover.
The technology does not replace laboratory research or medical expertise. Instead, it helps scientists make better-informed decisions about which biological targets deserve further investigation. Identifying the right target early is important because developing a medicine requires years of research, testing, and investment. If researchers can reduce uncertainty at the discovery stage, they may be able to use laboratory resources more efficiently.
Once potential drug candidates are identified, AstraZeneca will lead the clinical development process, regulatory work and commercialisation. This division of responsibilities brings together insitro’s AI capabilities and AstraZeneca’s experience in testing medicines, navigating approval requirements and bringing treatments to market.
The agreement comes as pharmaceutical companies increasingly explore AI-powered drug discovery to improve research efficiency and identify new treatment opportunities. Traditional drug development can be expensive and time-consuming, with many promising candidates failing during testing. Artificial intelligence offers another way to analyse disease biology, evaluate potential targets, and guide early research, although successful outcomes are not guaranteed.
For AstraZeneca and Insitro, the partnership represents an opportunity to investigate complex diseases with substantial unmet medical needs. The real measure of success will be whether the collaboration produces safe and effective treatments that benefit patients. While it may take years for any resulting medicines to reach the market, the agreement highlights how AI biotechnology partnerships are becoming an important part of the future of pharmaceutical research.
